目的 探討金水寶膠囊聯(lián)合來氟米特片治療慢性腎小球腎炎的臨床療效。方法 選取2018年8月—2021年12月萬寧市人民醫(yī)院收治的79例慢性腎小球腎炎患者，按照隨機數(shù)字表法將所有患者分為對照組（39例）和治療組（40例）。對照組口服來氟米特片，2片/次，1次/d。治療組在對照組基礎上飯后30 min口服金水寶膠囊，5粒/次，3次/d。兩組患者連續(xù)治療8周。觀察兩組的臨床療效，比較兩組的24 h尿蛋白定量（24 h Upro）、紅細胞（RBC）、胱抑素C（Cys-C）、中性粒細胞明膠酶相關脂質運載蛋白（NGAL）、視黃醇結合蛋白（RBP）、尿微量白蛋白（mALB）。結果 治療后，治療組的總有效率為95.00%，對照組的總有效率為79.49%，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的24 h Upro、RBC、Cys-C明顯低于治療前（P＜0.05），且治療組的24 h Upro、RBC、Cys-C低于對照組，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的血清NGAL、RBP、mALB水平顯著降低（P＜0.05），治療組血清NGAL、RBP、mALB水平顯著低于對照組（P＜0.05）。結論 金水寶膠囊聯(lián)合來氟米特片治療慢性腎小球腎炎的療效確切，能改善腎功能，減輕腎組織損傷，安全性良好。

Objective To investigate the clinical efficacy of Jinshuibao Capsules combined with Leflunomide Tablets in treatment of chronic glomerulonephritis. Methods Patients (79 cases) with chronic glomerulonephritis in Wanning People’s Hospital from August 2018 to December 2021 were divided into the control group (39 cases) and the treatment group (40 cases) according to the random number table method. Patients in the control group were po administered with Leflunomide Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Jinshuibao Capsules 30 min after meal on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the 24 h Upro, RBC, Cys-C, NGAL, RBP, and mALB in two groups were compared. Results After treatment, the total effective rate was 95.00% in the treatment group and 79.49% in the control group, with a statistically significant difference (P < 0.05). After treatment, the 24 h Upro, RBC, and Cys-C in two groups were significantly lower than those before treatment (P < 0.05), and the 24 h Upro, RBC, and Cys-C in the treatment group were lower than those in the control group, with a statistically significant difference (P < 0.05). After treatment, the serum levels of NGAL, RBP, and mALB in two groups were significantly reduced (P< 0.05), and the serum levels of NGAL, RBP, and mALB in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Jinshuibao Capsules combined with Leflunomide Tablets is effective in treatment of chronic glomerulonephritis, can improve renal function, reduce renal tissue damage, and has good safety.

R983